Validation of a rapid test (VWF-LIA) for the quantitative determination of von Willebrand factor antigen in type 1 von Willebrand disease diagnosis within the European multicenter study MCMDM-1VWD

Castaman, Giancarlo; Tosetto, Alberto; Cappelletti, Anna; Goodeve, Anne; Federici, Augusto B.; Batlle, J.; Meyer, Dominique; Goudemand, Jenny; Eikenboom, Jeroen; Schneppenheim, Reinhard; Budde, Ulrich; Ingerslev, Jørgen; Lethagen, Stefan; Hill, F. G. H.; Peake, I. R.; Rodeghiero, Francesco

doi:10.1016/j.thromres.2010.06.013

Cited by 27 publications

(28 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The study also looked at the quickest way to measure VWF, and this was the focus of an article published in 2010, which used the VWF–LIA test to determine VWF:Ag in patients with type 1 VWD . Another paper computed the likelihood of having VWD as a function of the bleeding score, the VWF level and the number of first‐degree family members with a reduced VWF level .…”

Section: Type 1 Patients – Is the Most Common Type Of Vwd Fully Undermentioning

confidence: 99%

Third Åland islands conference on vonWillebrand disease, 26–28September 2012: meeting report

Berntorp

Fuchs²,

Makris

et al. 2013

Haemophilia

Self Cite

View full text Add to dashboard Cite

Summary The first meeting of international specialists in the field of von Willebrand disease (VWD) was held in the Åland islands in 1998 where Erik von Willebrand had first observed a bleeding disorder in some members of a family from Föglö and a summary of the meeting was published in 1999. The second meeting was held in 2010 and a report of the meeting was published in 2012. Topics covered included progress in understanding of VWD over the last 50 years; multimers; classification of VWD; pharmacokinetics and laboratory assays; genetics; treating the paediatric patient; prophylaxis; geriatrics; gene therapy and treatment guidelines. This third meeting held over 3 days covered the structure and function of von Willebrand factor (VWF); type 1 VWD, the most common form of the disease; a lifespan of pharmacokinetics in VWD; detecting inhibitors in VWD patients; and special challenges in understanding and treating the female VWD patient.

show abstract

Section: Type 1 Patients – Is the Most Common Type Of Vwd Fully Undermentioning

confidence: 99%

Third Åland islands conference on vonWillebrand disease, 26–28September 2012: meeting report

Berntorp

Fuchs²,

Makris

et al. 2013

Haemophilia

Self Cite

View full text Add to dashboard Cite

show abstract

“…42 Furthermore, VWF:CB can detect rare VWF mutations that exclusively affect collagen binding or variants with loss standard practice. 53,54 This assay provides a measurement of VWF:Ag compared with a 30% normal control and when run with a 100% normal control could provide a semiquantitative assessment of the test subject's VWF:Ag level. It is also critical for all VWF functional ratios created by our assay, which allows for analysis by LDA.…”

Section: Discussionmentioning

confidence: 99%

Rapid discrimination of the phenotypic variants of von Willebrand disease

Roberts

Morateck

Christopherson

et al. 2016

Blood

View full text Add to dashboard Cite

show abstract

“…Tab. 2), including the vWF antigen, for which the ELISA test is a well validated method of measurement (38)(39)(40). thawed, all assessed biomarkers are known to be stable in vitro for a long time (at least few years).…”

Section: Circulating Biomarkersmentioning

confidence: 99%

Rationale and design of the Hunting for the off-target propertIes of Ticagrelor on Endothelial function and other Circulating biomarkers in Humans (HI-TECH) trial

Ariotti

Leeuwen

Brugaletta

et al. 2017

American Heart Journal

View full text Add to dashboard Cite

show abstract

Validation of a rapid test (VWF-LIA) for the quantitative determination of von Willebrand factor antigen in type 1 von Willebrand disease diagnosis within the European multicenter study MCMDM-1VWD

Cited by 27 publications

References 16 publications

Third Åland islands conference on vonWillebrand disease, 26–28September 2012: meeting report

Third Åland islands conference on vonWillebrand disease, 26–28September 2012: meeting report

Rapid discrimination of the phenotypic variants of von Willebrand disease

Rationale and design of the Hunting for the off-target propertIes of Ticagrelor on Endothelial function and other Circulating biomarkers in Humans (HI-TECH) trial

Contact Info

Product

Resources

About